Biocryst Pharmaceuticals (BCRX) Long-Term Deferred Tax (2017)
Biocryst Pharmaceuticals' (BCRX) quarterly Long-Term Deferred Tax came in at $5.9 billion in Q4 2017, up 99900.0% on a QoQ basis from $5.9 million in Q1 2017.
Biocryst Pharmaceuticals (BCRX) Long-Term Deferred Tax (2017) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 1 years of Long-Term Deferred Tax data on file, last reported at $5.9 billion in Q4 2017.
- Quarterly Long-Term Deferred Tax changed N/A year-over-year to $5.9 billion in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $5.9 billion (changed N/A YoY) and the FY2017 annual result came in at $5.9 billion, changed N/A from the prior year.
- Long-Term Deferred Tax advanced to $5.9 billion in Q4 2017, from $5.9 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $5.9 billion in Q4 2017 to a low of $5.9 million in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Biocryst Pharmaceuticals | 2.43 Bn | 2.08 Bn | 214.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 5.95 Bn |
| Mar 31, 2017 | 5.95 Mn |